bioRxiv Science⌕ Search

Biology subjects

Paruchuri, A.

Publications and source records attributed to Paruchuri, A..

2 recordsLinked to original sources

Rapid Identification of Genomic Alterations in Tumors affecting lymphocyte Infiltration (RIGATonI)

Tumor genomic alterations have been associated with altered tumor immune microenvironments and therapeutic outcomes. These studies raise a critical question: are there additional genomic variations altering the immune microenvironment in tumors that can provide insight into mechanisms of immune evasion? This question is the backbone of precision immuno-oncology. Current computational approaches to estimate immunity in bulk RNA sequencing (RNAseq) from tumors include gene set enrichment analysis and cellular deconvolution, but these techniques do not consider the spatial organization of lymphocytes or connect immune phenotypes with gene activity. Our new software package, Rapid Identification of Genomic Alterations in Tumors affecting lymphocyte Infiltration (RIGATonI), addresses these two gaps in separate modules: the Immunity Module and the Function Module. Using pathologist-reviewed histology slides and paired bulk RNAseq expression data, we trained a machine learning algorithm to detect high, medium, and low levels of immune infiltration (Immunity Module). We validated this technique using a subset of pathologist-reviewed slides not included in the training data, multiplex immunohistochemistry, flow cytometry, and digital staining of The Cancer Genome Atlas (TCGA). In addition to immune infiltrate classification, RIGATonI leverages another novel machine learning algorithm for the prediction of gain- and loss-of-function genomic alterations (Function Module). We validated this approach using clinically relevant and function-impacting genomic alterations from the OncoKB database. Combining these two modules, we analyzed all genomic alterations present in solid tumors in TCGA for their resulting protein function and immune phenotype. We visualized these results on a publicly available website. To illustrate RIGATonIs potential to identify novel genomic variants with associated altered immune phenotypes, we describe increased anti-tumor immunity in renal cell carcinoma tumors harboring 14q deletions and confirmed these results with previously published single-cell RNA sequencing. Thus, we present our R package and online database, RIGATonI: an innovative software for precision immuno-oncology research.

bioinformatics↗

In Vitro Validation of Computationally Predicted Oncogenic Driver Mutations in EGFR Tyrosine Kinase Domain

Epidermal Growth Factor Receptor (EGFR) signaling is known to play essential roles in growth and development; nevertheless, overexpression and mutation of EGFR have been reported in several cancers. Non-small cell lung cancer (NSCLC), the most observed type of lung cancer, harbors the highest number of EGFR tyrosine kinase mutations and therefore, EGFR has become an important therapeutic target for treatment of these tumors. Tyrosine Kinase Inhibitors (TKIs) are found to be effective in patients whose tumors contain activating mutations in the tyrosine kinase region of the receptor. This would seem to be beneficial in the treatment of EGFR mutation-positive NSCLC patients but the activating mutations should be sensitive to TKIs. Earlier, a machine learning approach was developed to classify single amino acid polymorphisms (SAPs) in EGFR into driver (cancer-causing) and passenger (neutral) mutations using structural and functional features (Anoosha et al., 2015). This study screened all possible point mutations in EGFR and predicted a list of mutations with high probability of being a driver or a passenger. From this list, we selected 2 mutations (G729E and G719F) with high evolutionary conservation score for in vitro validation. If proven to be oncogenic drivers and sensitive to EGFR TKIs, these mutations can aid in the early diagnosis and successful therapy of EGFR mutation-positive NSCLC.

cancer biology↗